Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Halberd Corp HALB

Halberd Corporation is a holding company. The Company is engaged in the acquisition vehicle for established businesses. It is also developing treatments for neurodegenerative diseases, such as post-traumatic stress disorder/chronic traumatic encephalopathy (PTSD/ CTE), Alzheimer’s disease and Parkinson’s disease. It has two issued patents and four provisional patent applications related to the... see more

Recent & Breaking News (OTCPK:HALB)

Halberd Agrees to Animal Testing at Mississippi State University

Accesswire January 24, 2023

Halberd Corporation 2022 Year End CEO Letter and 2023 Goals

Accesswire January 3, 2023

Halberd Receives Several Strains of Antibiotic Resistant Bacteria from CDC to Test Laser Eradication

Accesswire December 6, 2022

"The Street Podcast" Features Halberd's "Groundbreaking" Cancer Treatment Approach. Listen Now!

Accesswire December 5, 2022

CORRECTION: Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant

Accesswire December 1, 2022

Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant

Accesswire November 30, 2022

Halberd Corporation Achieves Groundbreaking Pre-Clinical Endpoint by Eradicating Cancer Disease Antigen Linked to Breast Cancer

Accesswire November 17, 2022

Halberd Signs Development and Marketing Agreement for Medications & Nutraceuticals

Accesswire November 14, 2022

Hartman, CEO, and Dr. Felder, CTO of Halberd Corp Featured on The Street Reports Podcast

Accesswire October 27, 2022

Halberd Laser Therapy Eliminates over 90% of Multiple Antibiotic Resistant Bacteria in Minutes

Accesswire October 18, 2022

Halberd Progresses from Eliminating Top Brain Disease Antigens from CSF To Eradication of Interleukin-6 From Human Blood Serum

Accesswire October 12, 2022

Halberd Enters Strategic Alliance for Longevity, Alzheimer's Disease, and Cancer Early Detection, Prevention and Treatment

Accesswire September 27, 2022

Halberd Demonstrates Precise Control of Key Cancer Related T-Cell Protein

Accesswire August 23, 2022

NFL Retired Players Association Endorses Halberd Brain Injury Treatment Technology

Accesswire August 4, 2022

Halberd Corporation Discusses OTCQB Uplisting and Growing List of Proprietary Technologies with The Stock Day Podcast

Newsfile July 28, 2022

Halberd Corp. Launches "Halberd Cancer Therapeutics, LTD" Wholly Owned Subsidiary

Newsfile July 20, 2022

Halberd's Antibody Effective Against all 4 SARS-CoV-2 Mutations, Including Omicron

Accesswire July 14, 2022

Halberd Corporation Update, CEO Letter and 2022 Expectations

Accesswire July 12, 2022

Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer

Accesswire June 21, 2022

Halberd Corp. & Mississippi State University Discuss Animal Testing as Prelude to FDA Certification

Accesswire June 8, 2022